# Study to Assess the Optimal Renoprotective Dose of Aliskiren in Hypertensive Patients With Type 2 Diabetes and Incipient or Overt Nephropathy

> **NCT00464776** · PHASE1,PHASE2 · COMPLETED · sponsor: **Novartis** · enrollment: 26 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Aliskiren
- **DRUG:** Aliskiren
- **DRUG:** Aliskiren
- **DRUG:** Aliskiren

## Key facts

- **NCT ID:** NCT00464776
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2008-04
- **Final completion:** —
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2011-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00464776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00464776, "Study to Assess the Optimal Renoprotective Dose of Aliskiren in Hypertensive Patients With Type 2 Diabetes and Incipient or Overt Nephropathy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00464776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*